产品展示/Products
Traditional drug research and development are mainly based on natural active products or screening new drugs from existing compound data, but this method is highly random, blind, and inefficient. Medicinal chemists subsequently developed high-throughput screening (HTS) methods for drug discovery. Many pharmaceutical companies have also established compound libraries containing millions of small molecules and discovered many drug candidates. However, in drug screening with complex targets, HTS has been repeatedly frustrated. It is difficult to screen high-potential compounds, or the screened compounds have high false positives and poor drug-like properties. In this context, Fragment-based drug design (FBDD) came into being. Organic synthesis can transform miniature hits into effective lead compounds. The deficiencies in the current screening of compound libraries usually result in the need for a large amount of synthetic investment to achieve multi-directional fragment growth, which limits the efficiency of the mini-fragment hit modification process. To meet this challenge, we designed a library of highly soluble 3D structural diversity fragments.
The utility of X-ray-based fragment screening and the ability to achieve rapid analog synthesis:
品牌介绍:
TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化域科学家的研究提供业的产品和服务。TargetMol品牌的客户群分布于40多个国家和地区,已发展成为全球大的化合物库和小分子化合物研究供应商。
原创作者:上海陶术生物科技有限公司
同类相关产品/congeneric Product
相关文章/related articles